Information  X 
Enter a valid email address

XTL BIOPHARMACEUTICALS LTD (XTL)

  Print   

Monday 05 March, 2007

XTL BIOPHARMACEUTICALS LTD

XTL to Present at Oppenheimer’s Pain Manageme...


              XTL Biopharmaceuticals to Present at Oppenheimer's               
    "Positioning Investors for the Next Wave in Pain Management" Conference    

NEW YORK, NEW YORK, March 5, 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB;
LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's Chief
Executive Officer, is scheduled to present tomorrow at Oppenheimer's
"Positioning Investors for the Next Wave in Pain Management" Conference. Mr.
Bentsur will present an overview of Bicifadine, the Company's recently
in-licensed late-stage clinical compound for the treatment of neuropathic pain,
in a presentation titled: "Bicifadine - A New Idea for Neuropathic Pain." Mr.
Bentsur's presentation will take place on Tuesday, March 6, 2007, at 2:25pm-2:
40pm Eastern Standard Time followed by a question and answer session from 2:
55pm-3:15pm., at the Flatotel Hotel in New York City.

A live audio webcast of Mr. Bentsur's presentation will be available at: http:/
/www.wsw.com/webcast/opp/xtl.l/. An archived version of the webcast will be 
available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial
in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a
combination of two monoclonal antibodies against the hepatitis C virus -
presently in Phase 1 clinical trials in patients with chronic hepatitis C.
XTL's hepatitis C pipeline also includes several families of pre-clinical
hepatitis C small molecule inhibitors.  XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional drug
candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock
Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960


                                                                                                                                                                                                                                                          

a d v e r t i s e m e n t